Arpeggio Biosciences

Arpeggio Biosciences, founded in 2016 and based in Boulder, Colorado, is a private, pre-clinical biotech integrating AI with functional transcriptomic screening to discover small molecule drugs. The company has raised over $60 million from top life-sciences investors to advance its platform, which aims to systematically identify compounds that modulate disease-driving transcription factors and biological networks. Led by a seasoned team with deep pharmaceutical industry experience, Arpeggio is building a pipeline with an initial emphasis on lung cancer, targeting a high-value but historically challenging class of proteins.

Integrated AI/ML platform that uses high-throughput transcriptomic screening (RNA-seq) to profile the full cellular response to small molecules. The platform identifies compounds based on their 'transcriptomic fingerprint,' uses AI to deconvolve mechanism of action and predict network/transcription factor modulation, and enables systematic medicinal chemistry optimization.

Arpeggio competes with other AI-driven drug discovery companies (e.g., Recursion, Exscientia, Insilico Medicine) and biotechs focused on transcription factors (e.g., Foghorn Therapeutics). Its differentiation lies in its specific use of whole-transcriptome screening as a primary data source and its integrated focus on network biology. It also competes with large pharma internal AI efforts and traditional drug discovery approaches.